Cingulate Inc. (CING)
NASDAQ: CING · IEX Real-Time Price · USD
0.831
-0.019 (-2.21%)
Apr 25, 2024, 1:35 PM EDT - Market open
Company Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder.
The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults.
It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Dec 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Shane J. Schaffer Pharm.D., PharmD |
Contact Details
Address: 1901 W. 47th Place Kansas City, Kansas 66205 United States | |
| Phone | (913) 942-2300 |
| Website | cingulate.com |
Stock Details
| Ticker Symbol | CING |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001862150 |
| CUSIP Number | 17248W105 |
| ISIN Number | US17248W2044 |
| Employer ID | 86-3825535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shane J. Schaffer Pharm.D., PharmD | Chief Executive Officer and Chairman of the Board |
| Dr. Laurie A. Myers M.B.A., Ph.D. | Executive Vice President and Chief Operating Officer |
| Dr. Matthew N. Brams M.D. | Executive Vice President and Chief Medical Officer |
| Jennifer L. Callahan CPA | Senior Vice President and Chief Financial Officer |
| Dr. Raul R. Silva M.D. | Executive Vice President and Chief Science Officer |
| Thomas Dalton | Vice President of Investor and Public Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 4, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 3, 2024 | 424B4 | Prospectus |
| Apr 2, 2024 | EFFECT | Notice of Effectiveness |
| Apr 1, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 1, 2024 | 10-K | Annual Report |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 424B5 | Filing |
| Feb 28, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |